Erythropoietin (Epo) is one of many biologically active growth factors present in human and animal milk. Accumulating evidence shows important developmental roles for these milk‐borne growth factors. Although Epo is present in biologically relevant amounts in mammalian milk, the roles of Epo in milk are incompletely defined. A significant proportion of milk‐borne Epo resists proteolytic degradation. Epo receptors (EpoR) have been found on gastric mucosa and intestinal mucosa, and in mesenteric vessel endothelium. Evidence to date shows that intact Epo reaches these local organs, as well as distal organs. After feeding Epo, local gastrointestinal physiological effects are seen in suckling rats. In humans and rats, short‐term feeding of high‐dose Epo increases reticulocytes, but it is unclear whether sustained treatment increases red cell mass. Conclusion: Further work towards understanding the physiological and potential pharmacological roles of enterally administered Epo is necessary. Summary Evidence to date supports the theory that Epo is present in biologically relevant amounts in mammalian milk, is protected from gastrointestinal proteolytic degradation and probably plays a role in local neonatal gastrointestinal development. Animal data show that milk from hypoxic mothers appears to stimulate erythropoiesis better than pharmacological doses of Epo added to normal milk or formula. The lack of efficacy of pharmacological doses of rhEpo in studies to date may be secondary to several factors, including local utilization of the hormone, the need for Epo to work in conjunction with another hematopoietic growth factor in milk, or nutritional factors, such as iron deficiency, interfering with the rhEpo response. Whether milk‐borne Epo plays a significant role in stimulating erythropoiesis is still unclear and more work is necessary to determine the physiological and pharmacological roles of milk‐borne Epo.
Background: Primary Epstein-Barr virus (EBV) infection frequently occurs early after transplantation (Tx) in seronegative pediatric heart Tx recipients who receive organs from seropositive donors and is the key risk factor for the development of post-transplant lymphoproliferative disorder (PTLD). The routine use of post-Tx EBV-PCR monitoring offers the opportunity to study the time course of primary EBV infection and the influence of differing immunosuppressive regimens. Methods: We studied 15 consecutive seronegative recipients who received a primary heart Tx from a seropositive donor. All were managed with tacrolimus-based immunosuppression with 9/15 also receiving 5 days of induction with rabbit antithymocyte globulin (Thymoglobulin). Surveillance was by whole blood real-time EBV-PCR approximately monthly for the first 6 months, then every 2 months for 6 months, then approximately quarterly thereafter. Results: Mean age at transplant was 5.4 years, and mean donor age was 8 years. Positive donor EBV serostatus prior to any donor transfusion was confirmed in 6 cases. One patient developed PTLD. A total of 270 PCR measurements were made (average 18/pt). 12/15 experienced primary EBV infection with first positive PCR 24-307 days post-Tx; median 38 days (Thymoglobulin pts 33d vs. non-Thymoglobulin pts 93d). Of 12 patients who developed detectable viral loads, 7 (58%) did so within 6 weeks of Tx. Peak EBV viral load ranged from 2,600 to 380,000 copies/ml; median 28,500 copies/ml (Thymoglobulin pts 26,000 vs. non-Thymoglobulin pts 47,000). Time to peak viral load was 32-1023 days, median 177 (Thymoglobulin pts 121d vs. non-Thymoglobulin pts 239d). Of the 3 patients who never developed a measurable viral load, none had pre-transfusion confirmation of donor seropositive status. Seronegative recipients with seronegative donors have not demonstrated early (first six weeks) viral loads, and screening of filtered blood products are also EBV-PCR negative suggesting that the loads observed in this study were not due to blood product use during cardiopulmonary bypass. Conclusions: EBV seronegative pediatric Tx recipients receiving hearts from seropositive donors experience very early EBV infection with evidence of viremia often within 4-6 weeks of Tx. Induction therapy may be associated with earlier viremia. EBV-PCR screening more frequently than monthly maybe indicated early after Tx in this population if any form of experimental / therapeutic intervention is planned at the time of primary EBV infection. Tumor necrosis factor (TNF) plays a crucial role in the pathogenesis of graft-vs-host disease (GVHD), the major cause of treatment-related mortality (TRM) after allogeneic bone marrow transplantation (BMT). We tested the hypothesis that early rises in TNF (on day 7 following BMT) predict the development of significant GVHD and TRM. Ratios of soluble TNF receptor 1 (TNFR1) levels (day 7 level/pre-BMT level) was used as a surrogate marker for TNF in 440 myeloablative allogeneic BMT pts with a median age of 42y (range 0-65y)....
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.